BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed its 4-week oral BETR-001 GLP toxicology study in animals. The study demonstrated that BETR-001’s repeated dosing for 4 weeks is very well-tolerated. The study findings support a broad therapeutic window for the use of BETR-001 in humans.
Related news for (BETRF)
- BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001
- BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
- BetterLife Pharma Appoints Corporate Advisor
- BetterLife Pharma Appoints New Director
- Amendment of Disclosures in Past Management Information Circulars